Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Interventistico
Fase 2
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Sponsor: Fudan University
Ultimo Aggiornamento: 14 agosto 2024 Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.